A Phase III Double-Masked, Crossover, Vehicle-Controlled Clinical Trial Conducted in an Environmental Exposure Chamber (EEC) to Study Reproxalap, a Novel, Non-Antihistaminic, Non-Steroidal, Reactive Aldehyde Species Inhibitor for the Treatment for Allergic Conjunctivitis (AC)

Abstract

Reproxalap demonstrated significant reduction in AC signs/symptoms over Phases I-II clinical trials; therefore, a pivotal phase III study was conducted in an EEC which mimics the natural but controlled exposure to allergen, to test reproxalap’s efficacy for AC treatment (NCT04207736).